Clinical trialNCT03841357CompletedPhase 3Interventional

Preventing Extension of Oligoarticular Juvenile Idiopathic Arthritis JIA (Limit-JIA)

SponsorDuke UniversityEnrollment121Juvenile Idiopathic Arthritis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a research study to test whether a once-weekly injection of abatacept will prevent the progression of Juvenile Idiopathic Arthritis (JIA) to a more severe form. To evaluate the effectiveness of a 24-week course of treatment with abatacept plus usual care versus usual care to prevent polyarthritis (≥5 joints), uveitis, or treatment with other systemic medication within 18 months of randomization in children with recent-onset limited JIA.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Eveline Wu, MD
University of North Carolina, Chapel Hill
Principal Investigator
clinicaltrials.gov ↗
Laura Schanberg, MD
Duke University
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

19 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of California at San Francisco Medical Center
San Francisco, California, United States
the Children'S Hospital Colorado
Aurora, Colorado, United States
Shands at the University of Florida
Gainesville, Florida, United States
Riley Hospital for Children at Indiana University Health
Indianapolis, Indiana, United States
University of Iowa Hospitals of Clinics
Iowa City, Iowa, United States
University of Louisville School of Medicine/ Norton Charities Pediatric Clinical Research Unit
Louisville, Kentucky, United States
Boston Children'S Hospital
Boston, Massachusetts, United States
University of Minnesota; Children'S Hospital and Clinics of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
Hackensack University Medical Center
Hackensack, New Jersey, United States
Children'S Hospital at Montefiore/ Albert Einstein University Hospital
The Bronx, New York, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Cincinnati Children'S Hospital Medical Center
Cincinnati, Ohio, United States
Metrohealth System
Cleveland, Ohio, United States
Nationwide Children'S Hospital
Columbus, Ohio, United States
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Monroe Carell Jr Children'S Hospital at Vanderbilt
Nashville, Tennessee, United States
University of Utah
Salt Lake City, Utah, United States
Seattle Children'S Hospital
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Abatacept →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 29 Oct 2019
Primary completion: 22 Jan 2025
Completion: 22 Jan 2025
Last update posted: 23 Jan 2026
Registered enrollment: 121
Registry id: NCT03841357

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.